Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs?

Autor: Glintborg, Bente, Ibsen, Rikke, Bilbo, Rebecca Elisabeth Qwist, Lund Hetland, Merete, Kjellberg, Jakob

Publikováno v: Glintborg, B, Ibsen, R, Bilbo, R E Q, Lund Hetland, M & Kjellberg, J 2019, ' Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? ', RMD Open, vol. 5, no. 2, e001016 . https://doi.org/10.1136/rmdopen-2019-001016

Objectives In year 2016, Danish national guidelines included a mandatory switch of patients with inflammatory rheumatic diseases treated with originator etanercept (ETA) to biosimilar SB4 in routine care. We aimed to explore if switching lead to incr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2751::47642b278e94fd5e45debd3779787b71
https://curis.ku.dk/portal/da/publications/does-a-mandatory-nonmedical-switch-from-originator-to-biosimilar-etanercept-lead-to-increase-in-healthcare-use-and-costs(1ad5d6cb-ac50-4522-9f7f-76b281808270).html